Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: Results from VOYAGER

European Heart Journal - Cardiovascular Pharmacotherapy

Volumn 2, Issue 4, 2016, Pages 212-217

  Karlson, Björn W ^a,b   Wiklund, Olov ^b   Palmer, Michael K ^c   Nicholls, Stephen J ^d   Lundman, Pia ^e   Barter, Philip J ^f  

^a ASTRAZENECA R AND D   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c MANCHESTER METROPOLITAN UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF ADELAIDE   (Australia)

^e DANDERYD HOSPITAL   (Sweden)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Atorvastatin; Low density lipoprotein cholesterol; Rosuvastatin; Simvastatin; Variability

Indexed keywords

ATORVASTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; SIMVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); AGED; BLOOD; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; HYPERCHOLESTEROLEMIA; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; ATORVASTATIN CALCIUM; CHOLESTEROL, LDL; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; ROSUVASTATIN CALCIUM; SIMVASTATIN; TREATMENT OUTCOME;

EID: 84994470337     PISSN: 20556837     EISSN: 20556845     Source Type: Journal    
DOI: 10.1093/ehjcvp/pvw006     Document Type: Article

References (8)

1. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63: 2889-2934.
2. Weng TC, Yang YH, Lin SJ, Tai SH. A systematic review and meta-Analysis on the therapeutic equivalence of statins. J Clin Pharm Ther 2010;35:139-151.
3. Boekholdt SM, Hovingh GK, Mora S, Arsenault BJ, Amarenco P, Pedersen TR, LaRosa JC, Waters DD, DeMicco DA, Simes RJ, Keech AC, Colquhoun D, Hitman GA, Betteridge DJ, Clearfield MB, Downs JR, Colhoun HM, Gotto AM Jr, Ridker PM, Grundy SM, Kastelein JJ. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: A meta-Analysis of statin trials. J Am Coll Cardiol 2014;64:485-494.
4. Nicholls SJ, Brandrup-Wognsen G, Palmer M, Barter PJ. Meta-Analysis of comparative efficacy of increasing dose of atorvastatin versus rosuvastatin versus simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am J Cardiol 2010;105:69-76.
5. Karlson BW, Palmer MK, Nicholls SJ, Lundman P, Barter PJ. To what extent do highintensity statins reduce low-density lipoprotein cholesterol in each of the four statin benefit groups identified by the 2013 American College of Cardiology/American Heart Association guidelines? A VOYAGER meta-Analysis. Atherosclerosis 2015; 241:450-454.
6. Pedro-Botet J, Schaefer EJ, Bakker-Arkema RG, Black DM, Stein EM, Corella D, Ordovas JM. Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner. Atherosclerosis 2001;158:183-193.
7. Superko HR, Momary KM, Li Y. Statins personalized. Med Clin North Am 2012;96: 123-139.
8. Masson M, Lobo M, Maenent D, Viatgliano L, Rostan M, Siniawski D, Huerin M, Giorgio M. Response to statins in cardiovascular prevention: hypo-responders evaluation. Rev Argent Cardiol 2014;82:34-41.